ACTIVE_NOT_RECRUITING

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Talk to us

Conditions

Uveitis, PosteriorUveitis, IntermediateUveitis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Official Title

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

Quick Facts

Study Start:2024-09-11
Study Completion:2028-02-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06431373

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult subjects (18-75 years old)
  2. * Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
  3. * Active uveitic disease in at least 1 eye
  4. * Weight \> 40 kg with a body mass index ≤ 40 kg/m2
  1. 1. Lymphoproliferative disorder
  2. 2. active malignancy
  3. 3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
  4. 4. thrombosis or cerebrovascular ischemic event disease within the last 12 months
  5. 5. a high risk for herpes zoster reactivation
  6. 6. active or recent infections

Contacts and Locations

Study Locations (Sites)

Clinical Trial Site
Phoenix, Arizona, 85020
United States
Clinical Trial Site
Phoenix, Arizona, 85054
United States
Clinical Trial Site
Bakersfield, California, 93309
United States
Clinical Trial Site
Beverly Hills, California, 90211
United States
Clinical Trial Site
Fullerton, California, 92835
United States
Clinical Trial Site
Irvine, California, 92697
United States
Clinical Trial Site
La Jolla, California, 92093
United States
Clinical Trial Site
Los Angeles, California, 90033
United States
Clinical Trial Site
Los Angeles, California, 90095
United States
Clinical Trial Site
Modesto, California, 95356
United States
Clinical Trial Site
Sacramento, California, 92825
United States
Clinical Trial Site
Aurora, Colorado, 80045
United States
Clinical Trial Site
Denver, Colorado, 80246
United States
Clinical Trial Site
Fort Lauderdale, Florida, 33308
United States
Clinical Trial Site
St. Petersburg, Florida, 33711
United States
Clinical Trial Site
Chicago, Illinois, 60637
United States
Clinical Trial Site
Oak Park, Illinois, 60304
United States
Clinical Trial Site
Carmel, Indiana, 46290
United States
Clinical Trial Site
Prairie Village, Kansas, 66208
United States
Clinical Trial Site
Baltimore, Maryland, 21287
United States
Clinical Trial Site
Boston, Massachusetts, 02114
United States
Clinical Trial Site
Waltham, Massachusetts, 02451
United States
Clinical Trial Site
Ann Arbor, Michigan, 48105
United States
Clinical Trial Site
Detroit, Michigan, 48201
United States
Clinical Trial Site
Detroit, Michigan, 48202
United States
Clinical Trial Site
Minneapolis, Minnesota, 55455
United States
Clinical Trial Site
Rochester, Minnesota, 55905
United States
Clinical Trial Site
St Louis, Missouri, 63108
United States
Clinical Trial Site
Omaha, Nebraska, 68105
United States
Clinical Trial Site
Palisades Park, New Jersey, 07650
United States
NYU Langone Health
New York, New York, 10017
United States
Clinical Trial Site
Rochester, New York, 14642
United States
Clinical Trial Site
Durham, North Carolina, 27705
United States
Clinical Trial Site
Winston-Salem, North Carolina, 27157
United States
Clinical Trial Site
Cleveland, Ohio, 44106
United States
Clinical Trial Site
Cleveland, Ohio, 44195
United States
Clinical Trial Site
Columbus, Ohio, 43212
United States
Clinical Trial Site
Portland, Oregon, 97221
United States
Clinical Trial Site
Portland, Oregon, 97239
United States
Clinical Trial Site
Erie, Pennsylvania, 16507
United States
Clinical Trial Site
Philadelphia, Pennsylvania, 19107
United States
Clinical Trial Site
Philadelphia, Pennsylvania, 19141
United States
Clinical Trial Site
Greenville, South Carolina, 29605
United States
Clinical Trial Site
Nashville, Tennessee, 37232
United States
Clinical Trial Site
Austin, Texas, 78712
United States
Clinical Trial Site
Bellaire, Texas, 77401
United States
Clinical Trial Site
Dallas, Texas, 75390
United States
Clinical Trial Site
Houston, Texas, 77025
United States
Clinical Trial Site
Katy, Texas, 77494
United States
Clinical Trial Site
Plano, Texas, 75075
United States
Clinical Trial Site
Round Rock, Texas, 78681
United States
Clinical Trial Site
San Antonio, Texas, 78230
United States
Clinical Trial Site
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: Priovant Therapeutics, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-11
Study Completion Date2028-02-01

Study Record Updates

Study Start Date2024-09-11
Study Completion Date2028-02-01

Terms related to this study

Additional Relevant MeSH Terms

  • Uveitis, Posterior
  • Uveitis, Intermediate
  • Uveitis